AREA UNDER THE CURVE;
ARTICLE;
CONTROLLED DRUG RELEASE;
CONTROLLED STUDY;
CORRELATION ANALYSIS;
DRUG ABSORPTION;
DRUG CAPSULE;
DRUG FORMULATION;
DRUG HALF LIFE;
DRUG SOLUBILITY;
HUMAN;
HUMAN EXPERIMENT;
IMMEDIATE DRUG RELEASE;
IN VITRO STUDY;
IN VIVO STUDY;
MAXIMUM PLASMA CONCENTRATION;
MEAN RESIDENCE TIME;
NORMAL HUMAN;
SINGLE DRUG DOSE;
TIME TO MAXIMUM PLASMA CONCENTRATION;
ADMINISTRATION, ORAL;
ANTILIPEMIC AGENTS;
AREA UNDER CURVE;
BIOLOGICAL AVAILABILITY;
CAPSULES;
DRUGS, GENERIC;
GEMFIBROZIL;
HUMANS;
SOLUBILITY;
THERAPEUTIC EQUIVALENCY;
TIME FACTORS;
Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia
Todd PA, Ward A. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs 1988; 36: 314-339.
A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability
Amidon GL, Lennernas H, Shah V, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
Centre for Drug Evaluation and Research, Food and Drug Administration, Nov
Rudman A, Williams R. Guidance for Industry: Immediate Release Solid Oral Dosage Forms. Scale Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation. Centre for Drug Evaluation and Research, Food and Drug Administration, Nov. 1995
U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research CDER, September 26
Guidance For The Industry: Extended Release Solid Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlation. U.S. Department of Health, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), September 26 1997.
